Hudson Bay Capital Management LP raised its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 8.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,112,500 shares of the biopharmaceutical company's stock after buying an additional 82,500 shares during the quarter. Hudson Bay Capital Management LP owned approximately 0.59% of Arbutus Biopharma worth $3,638,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Invesco Ltd. lifted its stake in shares of Arbutus Biopharma by 5.7% in the 4th quarter. Invesco Ltd. now owns 69,831 shares of the biopharmaceutical company's stock valued at $228,000 after purchasing an additional 3,780 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Arbutus Biopharma by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 40,179 shares of the biopharmaceutical company's stock valued at $131,000 after purchasing an additional 3,870 shares in the last quarter. Clear Harbor Asset Management LLC lifted its position in Arbutus Biopharma by 6.7% during the 4th quarter. Clear Harbor Asset Management LLC now owns 79,761 shares of the biopharmaceutical company's stock worth $261,000 after acquiring an additional 5,000 shares in the last quarter. Teacher Retirement System of Texas lifted its position in Arbutus Biopharma by 18.7% during the 4th quarter. Teacher Retirement System of Texas now owns 42,144 shares of the biopharmaceutical company's stock worth $138,000 after acquiring an additional 6,644 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Arbutus Biopharma by 18.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 56,452 shares of the biopharmaceutical company's stock worth $185,000 after acquiring an additional 8,648 shares in the last quarter. 43.79% of the stock is owned by institutional investors and hedge funds.
Arbutus Biopharma Stock Down 1.3%
NASDAQ ABUS traded down $0.04 during trading hours on Friday, hitting $3.08. The company had a trading volume of 1,052,601 shares, compared to its average volume of 1,003,257. Arbutus Biopharma Co. has a fifty-two week low of $2.71 and a fifty-two week high of $4.73. The business has a fifty day simple moving average of $3.28 and a 200-day simple moving average of $3.38. The firm has a market cap of $589.76 million, a P/E ratio of -7.16 and a beta of 1.50.
Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.04). Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. The company had revenue of $1.76 million during the quarter, compared to analyst estimates of $2.54 million. Equities analysts forecast that Arbutus Biopharma Co. will post -0.39 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on the company. HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. StockNews.com raised Arbutus Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, March 29th. Finally, Chardan Capital reissued a "buy" rating and set a $5.00 price target on shares of Arbutus Biopharma in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $5.50.
View Our Latest Analysis on Arbutus Biopharma
About Arbutus Biopharma
(
Free Report)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Featured Articles
Before you consider Arbutus Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.
While Arbutus Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
